Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee

Journal of Pain and Symptom Management
Najib BabulKenneth Albert

Abstract

The efficacy and safety of a once-daily extended-release formulation of tramadol hydrochloride (tramadol ER) was evaluated in patients with moderate to severe chronic pain of osteoarthritis (OA). This was a randomized, double-blind, placebo-controlled, parallel-group, 12-week study. Eligible patients with radiographically confirmed OA of the knee meeting the American College of Rheumatology diagnostic criteria, defined by knee pain and presence of osteophytes, plus at least age >50 years, morning stiffness <30 minutes in duration, and/or crepitus, entered a 2-7 day washout period during which all analgesics were discontinued. When pain at the index knee joint reached > or =40 mm (0-100 mm VAS), patients were randomized to tramadol ER or placebo. Tramadol ER was initiated at 100 mg QD and increased to 200 mg QD by the end of 1 week of treatment. After the first week, further increases to tramadol ER 300 mg or 400 mg QD were allowed. Outcome measures included Arthritis Pain Intensity Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Arthritis Scale (WOMAC) Pain, Stiffness, Physical Function VAS subscales, Patient and Physician Global Assessment of Therapy, Sleep, dropouts due to insufficient therapeutic effec...Continue Reading

References

May 7, 1992·The New England Journal of Medicine·M B MaxR Dubner
Jan 1, 1991·Acta Oncologica·C H Wilder-SmithH J Senn
Jan 1, 1991·Agents and Actions·W EnglbergerJ Schneider
Mar 1, 1990·Clinical Pharmacology and Therapeutics·R Kishore-KumarR Dubner
Jan 1, 1988·Annals of the Rheumatic Diseases·T J LeighV Wright
Jul 2, 1987·European Journal of Pharmacology·K H Carlsson, I Jurna
Jan 1, 1983·Current Medical Research and Opinion·C E Steele, W L Jefferson
Jul 1, 1982·The Journal of Nervous and Mental Disease·R M WittigT Roth
Dec 10, 1998·JAMA : the Journal of the American Medical Association·M RowbothamL Magnus-Miller
Jan 5, 1999·The Clinical Journal of Pain·C M MorinJ Wade
Jan 12, 2001·The Clinical Journal of Pain·L A MenefeeL Perez-Schwartz
Jun 8, 2001·MMWR. Morbidity and Mortality Weekly Report·UNKNOWN Centers for Disease Control and Prevention (CDC)
Oct 1, 2000·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·R J Rothenberg, J P Holcomb

❮ Previous
Next ❯

Citations

Jan 22, 2009·Der Anaesthesist·H L Rittner, A Brack
Oct 14, 2004·Rheumatology International·Gabriel Herrero-BeaumontUte Richarz
Oct 12, 2012·Zeitschrift für Rheumatologie·W W BoltenUNKNOWN und die Kommission Pharmakotherapie der Deutschen Gesellschaft für Rheumatologie
Jul 6, 2011·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Alexander BrackChristoph Stein
May 17, 2005·Journal of Dermatological Science·Fariba NayeriLars Brudin
Apr 23, 2009·Evidence-based Complementary and Alternative Medicine : ECAM·Sheila A Doggrell
Jan 2, 2007·The Nurse Practitioner·Yvonne D'Arcy
Nov 3, 2006·American Journal of Physical Medicine & Rehabilitation·Todd P StitikPatrick M Foye
May 23, 2008·American Journal of Therapeutics·Warren A Katz, Robert L Barkin
May 23, 2008·American Journal of Therapeutics·Allan Gibofsky, Robert L Barkin
Sep 23, 2009·International Journal of Clinical Practice·M T Rosenberg
Mar 24, 2009·Annales Françaises D'anesthèsie Et De Rèanimation·E MarretC Lejus
Dec 7, 2007·Expert Review of Neurotherapeutics·Gérald Mongin
Nov 2, 2013·Expert Review of Neurotherapeutics·Nalini SehgalHoward S Smith
May 26, 2011·Expert Opinion on Pharmacotherapy·Joseph V PergolizziRobert B Raffa
Aug 24, 2006·Expert Opinion on Pharmacotherapy·Consalvo Mattia, Flaminia Coluzzi
Jul 16, 2010·Expert Opinion on Pharmacotherapy·Robert Zorba Paster
Jul 11, 2006·Expert Opinion on Drug Delivery·Paul Sloan, Najib Babul
Mar 25, 2008·Current Medical Research and Opinion·Jeff R ScheinJohn D Freedman
Jul 13, 2006·Current Medical Research and Opinion·Theophilus J GanaUNKNOWN 023 Study Group
Oct 22, 2005·Current Medical Research and Opinion·J DevulderS H Nataraja
Jun 15, 2007·Current Medical Research and Opinion·Mark KosinskiJohn Freedman
Feb 10, 2007·Current Medical Research and Opinion·Bindu P MurthyBruce L Moskovitz
Nov 26, 2009·Current Medical Research and Opinion·Paul C LangleyJeff R Schein
Oct 3, 2012·Acta Anaesthesiologica Taiwanica : Official Journal of the Taiwan Society of Anesthesiologists·Shao-Keh HsuYi-Jer Hsieh
Oct 12, 2013·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Edward MichnaMei Sheng
Mar 31, 2010·Disease-a-month : DM·Warren A Katz, Robert L Barkin
Jan 13, 2009·Seminars in Arthritis and Rheumatism·Dennis C Turk, Mitchell J M Cohen
Mar 7, 2009·Pain Management Nursing : Official Journal of the American Society of Pain Management Nurses·Christine Miaskowski
Oct 29, 2008·The Veterinary Clinics of North America. Small Animal Practice·Spencer A JohnstonSteven C Budsberg
Jul 22, 2008·Rheumatic Diseases Clinics of North America·Warren A Katz
Jan 26, 2008·Clinical Therapeutics·Mark KosinskiJeff Schein
Jun 23, 2007·Journal of Pain and Symptom Management·Francis BurchSylvie Bouchard

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.